e-learning
resources
ERJ
2003
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Xanthine oxidase inhibition reduces reactive nitrogen species production in COPD airways
Ichinose M., Sugiura H., Yamagata S., Koarai A., Tomaki M., Ogawa H., Komaki Y., Barnes P.J., Shirato K., Hattori T.
Source:
Eur Respir J 2003; 22: 457-461
Journal Issue:
September
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Ichinose M., Sugiura H., Yamagata S., Koarai A., Tomaki M., Ogawa H., Komaki Y., Barnes P.J., Shirato K., Hattori T.. Xanthine oxidase inhibition reduces reactive nitrogen species production in COPD airways. Eur Respir J 2003; 22: 457-461
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
Evidence-based eHealth for COPD
Related content which might interest you:
Exhaled nitric oxide and hydrogen peroxide in patients with asthma and chronic obstructive pulmonary disease
Source: Eur Respir J 2007; 30: Suppl. 51, 617s
Year: 2007
Xanthine oxidase inhibition reduces reactive nitrogen species production in COPD airways
Source: Eur Respir J 2004; 23: 496
Year: 2004
Increased alveolar nitric oxide concentration in asthmatic patients with nocturnal symptoms
Source: Eur Respir J 2002; 20: 841-845
Year: 2002
Sputum neutrophilia is correlated with levels of exhaled nitric oxide (NO) in patients with chronic, stable sarcoidosis
Source: Eur Respir J 2001; 18: Suppl. 33, 344s
Year: 2001
Fractional exhaled nitric oxide in chronic obstructive pulmonary disease
Source: International Congress 2015 – Exhaled biomarkers in monitoring airways disease
Year: 2015
Fractional exhaled nitric oxide in patients with chronic obstructive pulmonary disease
Source: International Congress 2019 – FeNO in airway diseases and asthma-COPD overlap identification
Year: 2019
Increased nitrotyrosine in exhaled breath condensate in cystic fibrosis
Source: Eur Respir J 2001; 17: 1201-1207
Year: 2001
Differential assessment of airway inflammation in chronic obstructive pulmonary disease (COPD) by measurements of exhaled nitric oxide (NO) derived from peripheral
vs.
central airways
Source: Eur Respir J 2003; 22: Suppl. 45, 279s
Year: 2003
Exhaled nitric oxide in respiratory diseases other than asthma
Source: Eur Respir Monogr 2010; 49: 45-55
Year: 2010
Hyperinflation is associated with reduced nitric oxide production in COPD
Source: Eur Respir J 2005; 26: Suppl. 49, 226s
Year: 2005
Bronchial and alveolar exhaled nitric oxide as a marker of systemic involvement in patients with Crohn‘s disease
Source: Annual Congress 2011 - Role of the biomarkers in airway diseases
Year: 2011
Reactive oxygen species generation and exhaled nitric oxide in atopic mild bronchial asthma in exacerbation
Source: Eur Respir J 2002; 20: Suppl. 38, 49s
Year: 2002
Severity of scleroderma lung disease is related to alveolar concentration of nitric oxide
Source: Eur Respir J 2007; 30: 26-30
Year: 2007
Use of different exhaled nitric oxide multiple flow rate models in COPD
Source: Eur Respir J 2007; 29: 651-659
Year: 2007
Increased eNO and pulmonary iNOS expression in eNOS null mice
Source: Eur Respir J 2003; 21: 770-773
Year: 2003
Exhaled nitric oxide in chronic obstructive pulmonary disease: relationship to pulmonary function
Source: Eur Respir J 2001; 17: 934-938
Year: 2001
Superiority of hydrogen peroxide to exhaled nitric oxide as a marker of bronchial inflammation in asthmatic children
Source: Annual Congress 2008 - Paediatric airway diseases - pathophysiology and monitoring
Year: 2008
The use of exhaled nitric oxide concentration as a means of excluding eosinophilic inflammation in chronic cough
Source: Annual Congress 2009 - From cough to sound analysis of breathing
Year: 2009
Bronchial nitric oxide is related to symptom relief during fluticasone treatment in COPD
Source: Eur Respir J 2010; 35: 72-78
Year: 2010
Utility of exhaled nitric oxide as a noninvasive biomarker of lung inflammation in a disease model
Source: Eur Respir J 2006; 28: 1236-1244
Year: 2006
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept